[1]赵 鹏,刘 冬,兰 飞,等.非小细胞肺癌化疗前后血清糖类抗原125、基质金属蛋白酶-9、可溶性程序性死亡配体1水平变化及其与疗效关系研究[J].陕西医学杂志,2022,51(12):1564-1567.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.023]
　ZHAO Peng,LIU Dong,LAN Fei,et al.Changes of serum CA125,MMP-9 and sPD-L1 levels before and after chemotherapy in non-small cell lung cancer and their relationship with therapeutic effect[J].,2022,51(12):1564-1567.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.023]
点击复制

非小细胞肺癌化疗前后血清糖类抗原125、基质金属蛋白酶-9、可溶性程序性死亡配体1水平变化及其与疗效关系研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年12期
页码:
1564-1567
栏目:
临床研究
出版日期:
2022-12-05

文章信息/Info

Title:
Changes of serum CA125,MMP-9 and sPD-L1 levels before and after chemotherapy in non-small cell lung cancer and their relationship with therapeutic effect
作者:
赵 鹏1; 刘 冬2; 兰 飞2; 刘红岗3; 张 卉4; 康艳霞2
(1.西安大兴医院肿瘤血液科,陕西 西安 710016; 2.空军军医大学唐都医院肿瘤科,陕西 西安 710038; 3.空军军医大学唐都医院胸外科,陕西 西安 710038; 4.泾阳县医院内科,陕西 泾阳 713700)
Author(s):
ZHAO Peng; LIU Dong; LAN Fei; LIU Honggang; ZHANG Hui; KANG Yanxia
(Department of Oncology and Hematology,Xi'an Daxing Hospital,Xi'an 710016,China)
关键词:
非小细胞肺癌;  化疗;  糖类抗原125;  基质金属蛋白酶-9;  可溶性程序性死亡配体1
Keywords:
Non-small cell lung cancer;  Chemotherapy;  Carbohydrate antigen 125;  Matrix metalloproteinase-9;  Soluble programmed death ligand-1
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2022.12.023
文献标志码:
A
摘要:
目的:分析非小细胞肺癌(NSCLC)患者化疗前后血清糖类抗原(CA)125、基质金属蛋白酶-9(MMP-9)、可溶性程序性死亡配体1(sPD-L1)水平变化及其与疗效的关系。方法:选择接受顺铂+依托泊苷(EP)化疗的NSCLC患者95例为研究对象。采集所有患者化疗前和化疗后2个周期时的外周血,检测血清CA125、MMP-9、sPD-L1水平。于化疗4周后评价疗效。比较化疗前后及不同疗效NSCLC患者血清CA125、MMP-9、sPD-L1水平。采用Logistic回归分析血清CA125、MMP-9、sPD-L1水平与疗效的关系。采用受试者工作特征(ROC)曲线分析血清CA125、MMP-9、sPD-L1水平对化疗疗效的预测价值。结果:化疗后NSCLC患者血清CA125、MMP-9较化疗前显著下降(均P<0.05),PD-L1与治疗前比较差异无统计学意义(P>0.05)。部分缓解(PR)和疾病稳定(SD)的NSCLC患者化疗后血清CA125、MMP-9、PD-L1较化疗前下降,疾病进展(PD)的NSCLC患者血清CA125、MMP-9、PD-L1较化疗前上升(均P<0.05)。化疗前后血清CA125、MMP-9、PD-L1是NSCLC患者化疗疗效的独立影响因素。NSCLC患者化疗后血清CA125、MMP-9、PD-L1均对化疗疗效有较高的预测价值。结论:NSCLC患者化疗后血清CA125、MMP-9、sPD-L1水平与化疗疗效存在密切关联,对化疗疗效有较高的预测价值。
Abstract:
Objective:To analyze the changes of serum carbohydrate antigen(CA)125,matrix metalloproteinase-9(MMP-9)and soluble programmed death ligand-1(sPD-L1)levels before and after chemotherapy in non-small cell lung cancer(NSCLC)and their relationship with therapeutic effect.Methods:A total of 95 NSCLC patients who underwent cisplatin combined with etoposide(EP)chemotherapy were selected as the research subjects.The peripheral blood of all patients before chemotherapy and 2 cycles after chemotherapy was collected to detect serum CA125,MMP-9 and sPD-L1 levels.The therapeutic effect was evaluated after 4 weeks of chemotherapy.The serum CA125,MMP-9 and sPD-L1 levels were compared before and after chemotherapy and in NSCLC patients with different curative effects.Logistic regression was used to analyze the relationship between serum CA125,MMP-9,sPD-L1 levels and therapeutic effect.ROC curve was used to analyze the predictive value of serum CA125,MMP-9 and sPD-L1 levels on chemotherapy efficacy.Results:After chemotherapy,serum CA125 and MMP-9 in NSCLC patients were significantly decreased compared with those before chemotherapy(all P<0.05),and there was no significant difference in PD-L1 compared with that before treatment(P>0.05).The serum CA125,MMP-9 and PD-L1 of NSCLC patients with partial remission(PR)and stable disease(SD)decreased after chemotherapy compared with those before chemotherapy,while the serum CA125,MMP-9 and PD-L1 of NSCLC patients with progressive disease(PD)increased compared with those before chemotherapy(all P<0.05).Serum CA125,MMP-9 and PD-L1 before and after chemotherapy were independent influencing factors of chemotherapy efficacy in NSCLC patients.Serum CA125,MMP-9 and PD-L1 in NSCLC patients after chemotherapy had high predictive value for chemotherapy efficacy.Conclusion:The levels of serum CA125,MMP-9 and sPD-L1 are closely related to the therapeutic effect in non-small cell lung cancer patients after chemotherapy,which are of high predictive efficiency for therapeutic effect of chemotherapy.

参考文献/References:

[1] Omar AR.Outcomes of surgery as part of the management of metastatic non-small-cell lung cancer:A surveillance,epidemiology and end results database analysis[J].Cancer Invest,2018,36(4):238-245.
[2] Toyoaki H,Takashi S,Hidehito H,et al.Phase 2 study of ceritinib in alectinib-pretreated patients with ALK-rearranged metastatic NSCLC in Japan:ASCEND-9[J].Cancer Sci,2018,109(9):2863-2872.
[3] 王理槐,孙银辉,张领兄,等.基于Wnt/β-catenin信号通路探讨血府逐瘀汤在非小细胞肺癌EGFR-TKI获得性耐药中的作用[J].陕西中医,2022,43(4):427-431.
[4] 贺春艳,吴月明.非小细胞肺癌患者缺氧诱导因子、血管内皮细胞生长因子表达水平及其临床意义[J].陕西医学杂志,2022,51(4):503-506.
[5] 彭 彦,王 燕,郝学志,等.多项肺系统肿瘤标志物异常在晚期肺腺癌治疗中的作用[J].中国肺癌杂志,2017,20(10):690-694.
[6] 夏威夷,夏 华,桑圣刚.血清骨桥蛋白、基质金属蛋白酶及血管内皮生长因子水平在老年肝癌治疗效果评价中的价值[J].中国老年学杂志,2018,38(13):57-60.
[7] 肖 鹏,张 晓,靳 超.程序性死亡配体-1表达对Ⅰ期肺腺癌术后患者预后的价值[J].中国现代医学杂志,2018,28(27):51-58.
[8] 支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2015,37(1):67-78.
[9] Eisenhauer EA,Therasse P,Bogaerts J,et al.11 new response evaluation criteria in solid tumors:RECIST guideline version 1.1[J].Eur J Cancer,2009,45(2):228-247.
[10] 刘亚杰,马晓波.肿瘤标志物GSTP1、CYFRA21-1及SCC-Ag对非小细胞肺癌的预后评估价值[J].中国现代医学杂志,2020,30(14):42-46.
[11] 郭 娜,周小果.4种肿瘤标记物联合血清铁蛋白早期诊断老年肺癌[J].中国老年学杂志,2019,39(7):63-65.
[12] 田德全,徐 婷,张 燕,等.血清肿瘤标志物在晚期肺癌患者一线化疗疗效评估和生存预测中的价值[J].中华检验医学杂志,2017,40(9):693-699.
[13] 于永涛,佟 倜.克唑替尼对晚期非小细胞肺癌患者外周血清基质金属蛋白酶9的影响[J].中国药业,2018,27(6):75-77.
[14] 周 昱.结肠癌组织中基质金属蛋白酶9、转录因子1与细丝蛋白A的表达研究[J].中国现代医学杂志,2018,28(27):59-62.
[15] 王自全,王保庆,李庆妍.替吉奥联合长春瑞滨治疗进展期非小细胞肺癌的疗效以及对COX-2和MMP-9水平的影响[J].实用癌症杂志,2018,33(11):41-44.
[16] 王月华.PD-1/PD-L1在肿瘤免疫逃逸中的作用机制及其临床应用[J].中国肿瘤生物治疗杂志,2017,24(7):784-790.
[17] 薛文姬,毕 楠,杨 琳,等.PD-L1在同步放化疗非EGFR突变局部晚期非小细胞肺癌中的表达及其与患者预后的关系[J].中华医学杂志,2022,102(6):406-411.
[18] 赵 宁,任红亮,潘 娜,等.非小细胞肺癌组织PD-L1的表达及其与临床因素的关系[J].中国肿瘤生物治疗杂志,2017,24(3):284-289.
[19] 赵 爽,熊 芳.sPD-L1在肺癌患者血清及胸膜腔积液中水平差异及相关性分析[J].中国实验诊断学,2020,24(4):586-589.
[20] 田 浩,康晓艳,杨 琳,等.外周血sPD-L1在小细胞肺癌患者化疗期间变化及其临床意义[J].中国肿瘤临床,2019,46(9):452-456.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[3]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(12):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[4]邵渊.上颌窦癌临床特征及治疗[J].陕西医学杂志,2021,50(4):387.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.001]
[5]雷 普,卢红梅,卜小斌,等.新型内分泌联合化疗治疗高危前列腺癌临床研究[J].陕西医学杂志,2021,50(4):454.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.018]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]常瑞霞,可春梅.血小板相关参数和凝血指标在肺癌治疗中的变化及意义[J].陕西医学杂志,2021,50(5):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
　CHANG Ruixia,KE Chunmei.Changes and significance of platelet-related parameters and coagulation indexes in treatment of lung cancer[J].,2021,50(12):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
[8]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(12):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[9]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(12):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[10]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(12):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[11]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(12):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[12]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(12):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2019SF-085)
更新日期/Last Update: 2022-12-05